NewAmsterdam Pharma Company NV (NASDAQ:NAMS) Eyes Regulatory Catalysts That Could Reprice Shares
Obicetrapib program momentum and regulatory sequencing set the near-term narrative; current technicals point to constrained upside while fundamentals show a cash-rich but loss-making profile that supports continued development spend.






